English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

There is emerging evidence suggesting sphingolipids as critical regulators of cancer development and progression. Sphingolipids are potent bioactive lipids involved in fundamental biological processes including cell proliferation, apoptosis, angiogenesis, senescence, stress response and transformation. Ceramide, sphingosine and Sphingosine-1-phosphate (S1P) are inter-convertible sphingolipids with opposing effects on cell fate. Furthermore, S1P either acts directly on intracellular targets or through Gprotein coupled S1PRs (S1P1-5) to mediate their specific effects. This review will discuss the roles of key sphingolipids, sphingosine kinases (SphKs) and S1P receptors (S1PRs) in tumor growth and acquisition of resistance to chemotherapy in four subtypes of breast cancer that are categorized based on the status of hormone receptors and human epidermal growth factor 2 (HER2) receptors.

Involvement of Sphingosine Kinases/Sphingosine-1-Phosphate (S1P)/S1P Receptors in Breast Cancer Subtypes